Autopsy report · NCT00860158

Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer

“Slow accrual; closed by funder”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 9 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 5 years 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Noah Hahn, M.D.

Sponsor type

University, hospital or other

Conditions

Prostate Cancer

Interventions

Dasatinib; Leuprolide Acetate (LHRH Analogue); Radical Prostatectomy

Participants

1

Sites

6

Countries

United States

Trials that died the same way

• Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
  “Closed due to very slow accrual” (80% match in meaning)
• Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
  “Closed early due to slow accrual” (78% match in meaning)
• Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
  “Stopped due to slow accrual” (73% match in meaning)
• A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
  “Slow accrual, Funding stopped” (72% match in meaning)
• Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure
  “slow accrual; insufficient funding to continue to accrue” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.